HCPLive Network

Phase III Study Results for Levomilnacipran Promising

Forest Laboratories and Pierre Fabre Medicament made an announcement today stating that the main goal of their phase three study for levomilnacipran, a possible future treatment of major depressive disorder (MDD), had been achieved.

These recent findings are a relief for the two developmental partners as well as the medical community, especially since a previous phase three study earlier this year of levomilnacipran failed to exhibit optimistic results; the findings of that study showed that the drug decreased depression no more effectively than a placebo.

The purpose of this double-blind, randomized, placebo-controlled study was to test the drug's efficacy, safety, and tolerability.

The eight-week trial focused on 720 patients, whose depression was measured by the six-point Montgomery-Asberg Depression Rating Scale (MADRS). The researchers found that levomilnacipran decreased the depression of the participants, and further, they discovered that the participant’s scores lowered as doses increased.

MDD is estimated to affect roughly fifteen-million people in the United States each year.

"Depressed patients often struggle to find the right antidepressant and the need for new medications is high," said Dr. Marco Taglietti, Forest president and senior vice president of research and development.

The drug works through inhibiting the re-uptake of norepinephrine and serotonin, which increases the levels of these two neurotransmitters that are known to affect mood.

"These positive Phase III results are very encouraging and support the continued research of levomilnacipran in adult patients with major depressive disorder," concluded Taglietti.
 

Further Reading
Peripheral neuropathy was found in a third of HIV patients in a recent study of 58 men with a median age of 36 years.
Men who are socially well-integrated show more than a 2-fold reduced risk of suicide, according to a longitudinal study published in the Annals of Internal Medicine.
When a patient gets bitten by a dog, there can be many issues doctors need to confront as treatment begins. Two doctors shared their experiences of a patient who was bitten by a dog and still had symptoms including swelling and pain 2 weeks after his K-9 encounter.
A prognostic model has been developed and validated which has adequate discrimination for major outcomes in type 1 diabetes, according to a study published online Aug. 28 in Diabetologia.
High sodium intake is associated with increased disease activity in multiple sclerosis, according to research published online Aug. 28 in the Journal of Neurology, Neurosurgery & Psychiatry.
The costs of Medicare associated with Sovaldi (sofosbuvir), an emerging hepatitis C drug, will vary depending on how many people are given the treatment, a blog in Health Affairs found.
From 2000 to 2009 there was an increase in surgical treatment for spinal metastasis in the United States, which was accompanied by increased complication rates and costs, according to a study published in the Sept. 1 issue of The Spine Journal.
More Reading